Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Rubius Therapeutics Inc.

    NASDAQ: RUBY · Real-Time Price · USD
    0.06
    0.00 (8.11%)
    At close: Dec 29, 2023, 8:49 PM

    Rubius Therapeutics Statistics

    Share Statistics

    Rubius Therapeutics has 0 shares outstanding. The number of shares has increased by 0% in one year.

    Shares Outstanding

    n/a
    		 n/a

    Shares Change (YoY)

    n/a
    		 0%

    Shares Change (QoQ)

    n/a
    		 0%

    Owned by Institutions (%)

    n/a
    		 n/a

    Shares Floating

    n/a
    		 n/a

    Failed to Deliver (FTD) Shares

    n/a
    		 1

    FTD / Avg. Volume

    n/a
    		 n/a

    Short Selling Information

    Short Interest

    n/a
    		 n/a

    Short % of Shares Out

    n/a
    		 n/a

    Short % of Float

    n/a
    		 n/a

    Short Ratio (days to cover)

    n/a
    		 n/a

    Valuation Ratios

    The PE ratio is -0.07 and the forward PE ratio is null. Rubius Therapeutics's PEG ratio is 0.

    PE Ratio

    n/a
    		 -0.07

    Forward PE

    n/a
    		 n/a

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 n/a

    PB Ratio

    n/a
    		 1.04

    P/FCF Ratio

    n/a
    		 -0.1

    PEG Ratio

    n/a
    		 0
    Financial Ratio History

    Enterprise Valuation

    Rubius Therapeutics has an Enterprise Value (EV) of 2.04M.

    EV / Sales

    n/a
    		 0

    EV / EBITDA

    n/a
    		 -0.02

    EV / EBIT

    n/a
    		 -0.01

    EV / FCF

    n/a
    		 -0.01

    Financial Position

    The company has a current ratio of 2.54, with a Debt / Equity ratio of 0.07.

    Current Ratio

    n/a
    		 2.54

    Quick Ratio

    n/a
    		 2.54

    Debt / Equity

    n/a
    		 0.07

    Debt / EBITDA

    n/a
    		 -0.01

    Debt / FCF

    n/a
    		 -0.01

    Interest Coverage

    n/a
    		 -46.19

    Financial Efficiency

    Return on Equity is -1525.76% and Return on Invested Capital is -1412.7%.

    Return on Equity

    n/a
    		 -1525.76%

    Return on Assets

    n/a
    		 -1000.71%

    Return on Invested Capital

    n/a
    		 -1412.7%

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 $-38,477,166.67

    Employee Count

    n/a
    		 6

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 51.2M

    Effective Tax Rate

    n/a
    		 -28.5%

    Stock Price Statistics

    The stock price has increased by 5.26% in the last 52 weeks. The beta is 2.21, so Rubius Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 2.21

    52-Week Price Change

    n/a
    		 5.26%

    50-Day Moving Average

    n/a
    		 0.02

    200-Day Moving Average

    n/a
    		 0.02

    Relative Strength Index (RSI)

    n/a
    		 87.52

    Average Volume (20 Days)

    n/a
    		 99,535

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 n/a

    Operating Income

    n/a
    		 -178.45M

    Net Income

    n/a
    		 -230.86M

    EBITDA

    n/a
    		 -118.35M

    EBIT

    n/a
    		 -175.8M

    Earnings Per Share (EPS)

    n/a
    		 -2.56
    Full Income Statement

    Balance Sheet

    The company has 14.87M in cash and 1.1M in debt, giving a net cash position of 13.77M.

    Cash & Cash Equivalents

    n/a
    		 14.87M

    Total Debt

    n/a
    		 1.1M

    Net Cash

    n/a
    		 13.77M

    Retained Earnings

    n/a
    		 -856.68M

    Total Assets

    n/a
    		 23.07M

    Working Capital

    n/a
    		 12.26M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -150.14M and capital expenditures -5.3M, giving a free cash flow of -155.45M.

    Operating Cash Flow

    n/a
    		 -150.14M

    Capital Expenditures

    n/a
    		 -5.3M

    Free Cash Flow

    n/a
    		 -155.45M

    FCF Per Share

    n/a
    		 -1.72
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    RUBY does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 -1460.84%

    FCF Yield

    n/a
    		 -983.62%
    Dividend Details

    Analyst Forecast

    Currently there are no analyst rating for RUBY.

    Price Target

    n/a
    		 n/a

    Price Target Difference

    n/a
    		 n/a

    Analyst Consensus

    n/a
    		 n/a

    Analyst Count

    n/a
    		 n/a
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -81.9

    Piotroski F-Score

    n/a
    		 2

    Add to Watchlist